Table 3.
Univariate and logistic regression model for clinical response
| Variable | Failure (n = 144) |
Response (n = 249) |
Pa | OR (95% CI) | Pb |
|---|---|---|---|---|---|
| Age, years | 58.0 (51.0–67.0) | 54.0 (47.0–63.0) | 0.009 | 0.98 (0.96–1.0) | 0.012 |
| SOFA score | 8.0 (7.0–12.0) | 8.0 (5.0–10.0) | 0.003 | ||
| APACHE II score | 19.0 (14.0–23.0) | 17.0 (11.0–21.0) | 0.001 | ||
| Septic shock | 69 (47.6%) | 84 (33.9%) | 0.007 | 0.55 (0.33–0.93) | 0.025 |
| Vasoactive drugs | 87 (60.8%) | 108 (44.4%) | 0.002 | ||
| Use of nephrotoxic drugs | 117 (80.7%) | 172 (69.4%) | 0.014 | 0.44 (0.24–0.83) | 0.011 |
| Laboratory data | |||||
| GFR, mL/min·1.73m2 | 96.0 (51.8–114.4) | 102.7 (73.7–118.0) | 0.049 | ||
| Albumin, g/L | 29.2 (26.2–33.2) | 30.5 (27.3–35.0) | 0.080 | ||
| Platelets, 109/L | 139.0(73.0–244.0) | 172.5 (85.5–271.0) | 0.008 | ||
| C-reactive protein, μg/L | 89.4 (45.9–150.0) | 67.6 (30.8–130.7) | 0.072 | ||
| Procalcitonin, ng/mL | 1.2 (0.5–4.0) | 0.9 (0.3–3.5) | 0.080 | ||
| Polymyxin B dose and exposure | |||||
| Dose/weight, mg/kg/day | 2.0 (1.6–2.3) | 2.1 (1.8–2.5) | 0.011 | ||
| Daily dose ≥ 150 mg/day | 82 (56.6%) | 185 (74.6%) | < 0.001 | ||
| AUCss,24 h ≥ 50 mg h/L | 63 (43.4%) | 175 (70.6%) | < 0.001 | 4.39 (2.56–7.47) | < 0.001 |
| cC0h > 1.01 mg/L | 79 (54.9%) | 169 (67.9%) | < 0.001 | ||
OR odds ratio; CI confidence interval; GFR glomerular filtration rate; and AUCss,24 h the area under the curve across 24 h at steady state
aderived from univariate analysis
bderived from logistic regression analysis
cC0h was not included in the logistic regression model due to collinearity with AUCss,24 h